Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 UCB Submits BLA for Crohn's Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

UCB Submits BLA for Crohn’s Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

UCB has submitted a BLA to the FDA for the approval of Cimzia for the treatment of Crohn’s disease. If approved, Cimzia would be the first-ever biologic utilizing subcutaneous injection for the treatment of Crohn’s disease.

The BLA includes safety and efficacy data from clinical trials in more than 1,500 patients with Crohn’s disease. The studies (PRECiSE 1 and PRECiSE 2) that support the BLA submission met their primary endpoints by demonstrating that Cimzia induced clinical response and maintained clinical response and remission in a significant percentage of patients with Crohn’s disease. The Cimzia BLA package represents the largest biologic clinical trial database and broadest, in terms of patient types, submitted to the FDA for Crohn’s disease treatment, according to UCB.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics